# OnCo record radiohybrid-theranostics (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/radiohybrid-theranostics/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "radiohybrid-theranostics" ;
  schema:name "Radiohybrid theranostics (rhPSMA)"@en ;
  schema:alternateName "radiohybrid ligands"@en, "radiohybrid PSMA"@en, "rhPSMA"@en, "radiohybrid radiopharmaceuticals"@en ;
  schema:description "A radiohybrid molecule has two places to attach a radioactive atom. The same molecule can carry fluorine-18 for a PET scan or a metal such as lutetium-177 for treatment, so the scan shows exactly where the treatment version will go."@en ;
  schema:url <https://onco.cc/technologies/radiohybrid-theranostics/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.2967/jnumed.119.234922> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/imaging/> ;
  onco:technologies <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/flotufolastat/> ;
  onco:companies <https://onco.cc/companies/blue-earth-diagnostics/>, <https://onco.cc/companies/blue-earth-therapeutics/> ;
  onco:institutions <https://onco.cc/institutions/tum-munich/> ;
  onco:trials <https://onco.cc/trials/nct05413850/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05413850-j-nucl-med-2024/> .